https://scholars.lib.ntu.edu.tw/handle/123456789/551082
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHEN-HUA LIU | en_US |
dc.contributor.author | CHUN-JEN LIU | en_US |
dc.contributor.author | TUNG-HUNG SU | en_US |
dc.contributor.author | HUNG-CHIH YANG | en_US |
dc.contributor.author | CHUN-MING HONG | en_US |
dc.contributor.author | TAI-CHUNG TSENG | en_US |
dc.contributor.author | PEI-JER CHEN | en_US |
dc.contributor.author | DING-SHINN CHEN | en_US |
dc.contributor.author | JIA-HORNG KAO | en_US |
dc.date.accessioned | 2021-03-09T01:43:23Z | - |
dc.date.available | 2021-03-09T01:43:23Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042270551&doi=10.1111%2fjgh.13912&partnerID=40&md5=1c979ded0e67f55b6da553b1740c938b | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/551082 | - |
dc.description.abstract | Background and Aim: The real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) remain limited for East Asian hepatitis C virus genotype 1b (HCV-1b) patients. The study aimed to evaluate the antiviral responses of PrOD-based regimens for HCV-1b patients in Taiwan. Methods: The study performed a retrospective analysis of 103 HCV-1b patients receiving PrOD with or without ribavirin (RBV) for 12?weeks. Data were analyzed to assess the on-treatment and off-therapy HCV viral load and on-treatment adverse events. The pre-specified characteristics related to sustained virologic response 12?weeks off therapy (SVR12) were compared. Results: At treatment week 4, 100 of 102 patients (98.0%) had serum HCV RNA level <?25?IU/mL. The SVR12 was achieved in 101 of 103 patients (98.1%, [95% confidence interval: 93.2–99.5%]). All except one (99.0%) patients tolerated treatment well without treatment interruption. One cirrhotic patient discontinued treatment at week 1 due to hepatic decompensation. Twenty-four patients (23.3%) had ? grade 2 elevation in total bilirubin levels, and 21 of them (87.5%) had indirect type hyperbilirubinemia. The stratified SVR12 rates were comparable in terms of sex, age, body mass index, prior treatment experience, hepatitis B virus surface antigen status, RBV usage, baseline and week 2 viral load, renal function, and hepatic fibrosis stage. Conclusions: Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without RBV are efficacious and generally well tolerated for treatment of HCV-1b patients in Taiwan. ? 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd | en_US |
dc.publisher | Blackwell Publishing | en_US |
dc.relation.ispartof | Journal of Gastroenterology and Hepatology (Australia) | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alanine aminotransferase; aspartate aminotransferase; bilirubin; bilirubin glucuronide; dasabuvir; hepatitis B surface antigen; ombitasvir plus paritaprevir plus ritonavir; ribavirin; robatrol; virus RNA; ABT-267; ABT-333; ABT-450; anilide; antivirus agent; carbamic acid derivative; macrocyclic compound; ribavirin; ritonavir; sulfonamide; uracil; acute kidney failure; adult; aged; alanine aminotransferase blood level; antiviral therapy; arthralgia; Article; ascites; aspartate aminotransferase blood level; body mass; body weight gain; chronic hepatitis C; coughing; decompensated liver cirrhosis; diarrhea; drug efficacy; drug safety; drug withdrawal; dyspnea; fatigue; female; headache; Hepatitis C virus subtype 1b; human; hyperbilirubinemia; insomnia; kidney function; liver cell carcinoma; liver cirrhosis; liver fibrosis; major clinical study; male; nausea; priority journal; pruritus; retrospective study; side effect; sustained virologic response; Taiwan; treatment duration; treatment interruption; very elderly; virus load; analogs and derivatives; chronic hepatitis C; combination drug therapy; genetics; genotype; Hepacivirus; middle aged; safety; treatment outcome; virology; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Middle Aged; Retrospective Studies; Ribavirin; Ritonavir; Safety; Sulfonamides; Taiwan; Treatment Outcome; Uracil; Viral Load | - |
dc.title | Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1111/jgh.13912 | - |
dc.identifier.pmid | 28762541 | - |
dc.identifier.scopus | 2-s2.0-85042270551 | - |
dc.relation.pages | 710-717 | en_US |
dc.relation.journalvolume | 33 | en_US |
dc.relation.journalissue | 3 | en_US |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Microbiology | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Medical Research | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0003-3622-9707 | - |
crisitem.author.orcid | 0000-0002-6202-0993 | - |
crisitem.author.orcid | 0000-0002-6747-7941 | - |
crisitem.author.orcid | 0000-0003-3864-9895 | - |
crisitem.author.orcid | 0000-0002-0075-1280 | - |
crisitem.author.orcid | 0000-0001-8316-3785 | - |
crisitem.author.orcid | 0000-0001-7791-6154 | - |
crisitem.author.orcid | 0000-0002-2442-7952 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。